Literature DB >> 24338482

Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis.

Kazutaka Sumita1, Hirofumi Yoshino, Mika Sasaki, Nazanin Majd, Emily Rose Kahoud, Hidenori Takahashi, Koh Takeuchi, Taruho Kuroda, Susan Lee, Pascale G Charest, Kosuke Takeda, John M Asara, Richard A Firtel, Dimitrios Anastasiou, Atsuo T Sasaki.   

Abstract

Mammalian cells encode three closely related Ras proteins, H-Ras, N-Ras, and K-Ras. Oncogenic K-Ras mutations frequently occur in human cancers, which lead to dysregulated cell proliferation and genomic instability. However, mechanistic role of the Ras isoform regulation have remained largely unknown. Furthermore, the dynamics and function of negative regulation of GTP-loaded K-Ras have not been fully investigated. Here, we demonstrate RasG, the Dictyostelium orthologue of K-Ras, is targeted for degradation by polyubiquitination. Both ubiquitination and degradation of RasG were strictly associated with RasG activity. High resolution tandem mass spectrometry (LC-MS/MS) analysis indicated that RasG ubiquitination occurs at C-terminal lysines equivalent to lysines found in human K-Ras but not in H-Ras and N-Ras homologues. Substitution of these lysine residues with arginines (4KR-RasG) diminished RasG ubiquitination and increased RasG protein stability. Cells expressing 4KR-RasG failed to undergo proper cytokinesis and resulted in multinucleated cells. Ectopically expressed human K-Ras undergoes polyubiquitin-mediated degradation in Dictyostelium, whereas human H-Ras and a Dictyostelium H-Ras homologue (RasC) are refractory to ubiquitination. Our results indicate the existence of GTP-loaded K-Ras orthologue-specific degradation system in Dictyostelium, and further identification of the responsible E3-ligase may provide a novel therapeutic approach against K-Ras-mutated cancers.

Entities:  

Keywords:  Cancer Biology; Cytokinesis; Dictyostelium; Molecular Cell Biology; Ras; Signaling; Ubiquitination

Mesh:

Substances:

Year:  2013        PMID: 24338482      PMCID: PMC3924263          DOI: 10.1074/jbc.M113.531178

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Differential modification of Ras proteins by ubiquitination.

Authors:  Natalia Jura; Elizabeth Scotto-Lavino; Aleksander Sobczyk; Dafna Bar-Sagi
Journal:  Mol Cell       Date:  2006-03-03       Impact factor: 17.970

2.  Role of phosphatidylinositol 3-kinases in chemotaxis in Dictyostelium.

Authors:  Kosuke Takeda; Atsuo T Sasaki; Hyunjung Ha; Hyun-A Seung; Richard A Firtel
Journal:  J Biol Chem       Date:  2007-03-01       Impact factor: 5.157

3.  Dynamic properties of the Ras switch I region and its importance for binding to effectors.

Authors:  M Spoerner; C Herrmann; I R Vetter; H R Kalbitzer; A Wittinghofer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

4.  Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination.

Authors:  Rachael Baker; Emily M Wilkerson; Kazutaka Sumita; Daniel G Isom; Atsuo T Sasaki; Henrik G Dohlman; Sharon L Campbell
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

5.  Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility.

Authors:  J K Voice; R L Klemke; A Le; J H Jackson
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

6.  Feedback regulation of Ras signaling by Rabex-5-mediated ubiquitination.

Authors:  Lizhong Xu; Veronica Lubkov; Laura J Taylor; Dafna Bar-Sagi
Journal:  Curr Biol       Date:  2010-07-22       Impact factor: 10.834

Review 7.  The guanine nucleotide-binding switch in three dimensions.

Authors:  I R Vetter; A Wittinghofer
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

8.  Disruption of the Dictyostelium myosin heavy chain gene by homologous recombination.

Authors:  A De Lozanne; J A Spudich
Journal:  Science       Date:  1987-05-29       Impact factor: 47.728

9.  Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Authors:  Kevin M Haigis; Krystle R Kendall; Yufang Wang; Ann Cheung; Marcia C Haigis; Jonathan N Glickman; Michiko Niwa-Kawakita; Alejandro Sweet-Cordero; Judith Sebolt-Leopold; Kevin M Shannon; Jeffrey Settleman; Marco Giovannini; Tyler Jacks
Journal:  Nat Genet       Date:  2008-03-30       Impact factor: 38.330

10.  Inhibition of Cdc42 during mitotic exit is required for cytokinesis.

Authors:  Benjamin D Atkins; Satoshi Yoshida; Koji Saito; Chi-Fang Wu; Daniel J Lew; David Pellman
Journal:  J Cell Biol       Date:  2013-07-22       Impact factor: 10.539

View more
  4 in total

Review 1.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

2.  The ubiquitination of the influenza A virus PB1-F2 protein is crucial for its biological function.

Authors:  Ivan Košík; Margaréta Práznovská; Martina Košíková; Zuzana Bobišová; Jaroslav Hollý; Eva Varečková; František Kostolanský; Gustáv Russ
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

3.  Identification of lysine methylation in the core GTPase domain by GoMADScan.

Authors:  Hirofumi Yoshino; Guowei Yin; Risa Kawaguchi; Konstantin I Popov; Brenda Temple; Mika Sasaki; Satoshi Kofuji; Kara Wolfe; Kaori Kofuji; Koichi Okumura; Jaskirat Randhawa; Akshiv Malhotra; Nazanin Majd; Yoshiki Ikeda; Hiroko Shimada; Emily Rose Kahoud; Sasson Haviv; Shigeki Iwase; John M Asara; Sharon L Campbell; Atsuo T Sasaki
Journal:  PLoS One       Date:  2019-08-07       Impact factor: 3.240

Review 4.  Post-translational modification of KRAS: potential targets for cancer therapy.

Authors:  Wei-Hua Wang; Tao Yuan; Mei-Jia Qian; Fang-Jie Yan; Liu Yang; Qiao-Jun He; Bo Yang; Jin-Jian Lu; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-10-21       Impact factor: 7.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.